About us Contacts Drug interactions: 390 212
Drug search by name

Rasuvo and Sulfamethoxazole Trimethoprim Oral Suspension

Determining the interaction of Rasuvo and Sulfamethoxazole Trimethoprim Oral Suspension and the possibility of their joint administration.

Check result:
Rasuvo <> Sulfamethoxazole Trimethoprim Oral Suspension
Relevance: 03.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Methotrexate can cause impaired bone marrow function resulting in low numbers of different types of blood cells, and using it with trimethoprim can increase the risk. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration of methotrexate with trimethoprim may increase the risk of severe myelosuppression and megaloblastic anemia due to potential additive effects resulting from inhibition of dihydrofolate reductase by both drugs. The interaction has been reported primarily with sulfamethoxazole-trimethoprim, but has also occurred with trimethoprim alone. Most cases involved the elderly, often in association with renal impairment. Some were fatal. In one report, an 81-year-old woman receiving low-dose methotrexate (7.5 mg/week) for rheumatoid arthritis developed fatal pancytopenia following the addition of trimethoprim. The dosage of trimethoprim had been 100 mg/day for nearly two months, but was increased to 200 mg/day due to suspected urinary tract infection one week before admission to hospital. The patient's bone marrow failed to recover despite treatment with calcium folinate and granulocyte colony stimulating factor, and she died of bronchopneumonia one week after admission. Likewise, concomitant use of sulfamethoxazole-trimethoprim was identified as a risk factor for pancytopenia associated with low-dose methotrexate use over a 10-year period in a regional survey conducted by a group of investigators in Ottawa.

MANAGEMENT: Concomitant use of methotrexate with trimethoprim should be avoided if possible. Some clinicians consider the use of methotrexate with low-dose sulfamethoxazole-trimethoprim (e.g., for the prophylaxis of Pneumocystis jiroveci pneumonia) to be acceptable; however, close monitoring for hematologic toxicity is recommended, particularly in the elderly. Complete blood counts, liver enzymes, and serum creatinine levels should be performed at baseline and periodically during treatment. Folate supplementation may be required in some cases. Patients should be advised to notify their doctor if they experience signs and symptoms of bone marrow depression or anemia such as fever, chills, sore throat, easy bruising or bleeding, pallor, dizziness, fatigue, lethargy, sore mouth or tongue, and tingling in hands or feet.

References
  • Al-Quteimat OM, Al-Badaineh MA "Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination." J Clin Pharm Ther 38 (2013): 203-5
  • Jeurissen ME, Boerbooms AM, van de Putte LB "Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole." Ann Intern Med 111 (1989): 261
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Bourre-Tessier J, Haraoui B "Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review." J Rheumatol 37 (2010): 1416-21
  • al-Awadhi A, Dale P, McKendry RJ "Pancytopenia associated with low dose methotrexate therapy. A regional survey." J Rheumatol 20 (1993): 1121-5
  • "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  • Ng HW, Macfarlane AW, Graham RM, Verbov JL "Near fatal drug interactions with methotrexate given for psoriasis." Br Med J (Clin Res Ed) 295 (1987): 752-3
  • Furst DE "Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis." Br J Rheumatol 34 Suppl (1995): 20-5
  • Cudmore J, Seftel M, Sisler J, Zarychanski R "Methotrexate and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur." Can Fam Physician 60 (2014): 53-6
  • Steuer A, Gumpel JM "Methotrexate and trimethoprim: a fatal interaction." Br J Rheumatol 37 (1998): 105-6
  • Govert JA, Patton S, Fine RL "Pancytopenia from using trimethoprim and methotrexate." Ann Intern Med 117 (1992): 877-8
  • Maricic M, Davis M, Gall EP "Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment." Arthritis Rheum 29 (1986): 133-5
  • Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM "Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis." J Pediatr 120 (1992): 468-73
  • Thomas MH, Gutterman LA "Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole." J Rheumatol 13 (1986): 440-1
  • Kobrinsky NL, Ramsay NK "Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole." Ann Intern Med 94 (1981): 780-1
  • Chevrel G, Brantus JF, Sainte-Laudy J, Miossec P "Allergic pancytopenia to trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis." Rheumatology(Oxford) 38 (1999): 475-6
  • Yamazaki H, Nanki T, Miyasaka N, Harigai M "Methotrexate and trimethoprim-sulfamethoxazole for pneumocystis pneumonia prophylaxis." J Rheumatol 38 (2011): 777
  • Frain JB "Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole." J Rheumatol 14 (1987): 176-7
  • Saravana S, Lalukotta K "Myelotoxicity due to methotrexate - an iatrogenic cause." Eur J Haematol 71 (2003): 315-6
  • Verbov JL "Methotrexate and trimethoprim-sulfamethoxazole." Clin Exp Dermatol 16 (1991): 231
  • Thomas DR, Dover JS, Camp RD "Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole." J Am Acad Dermatol 17 (1987): 1055-6
  • Yang CH, Yang LJ, Jaing TH, Chan HL "Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole." Int J Dermatol 39 (2000): 621-3
Rasuvo

Generic Name: methotrexate

Brand name: Methotrexate Sodium, Preservative Free, Otrexup, Rasuvo, Rheumatrex Dose Pack, Trexall, Xatmep

Synonyms: Rasuvo (injection), Rasuvo Injection

Sulfamethoxazole Trimethoprim Oral Suspension

Generic Name: sulfamethoxazole / trimethoprim

Brand name: Bactrim, Bactrim DS, Bactrim IV, Septra IV, SMZ-TMP DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS

Synonyms: Sulfamethoxazole and trimethoprim, Sulfamethoxazole and Trimethoprim

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.